Clinical trials
Urothelial Carcinoma Recurrent clinical trials
Below are recruiting urothelial carcinoma recurrent clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide for early-stage bladder cancer
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Tucson, ArizonaAges 18 years+ - NCT05037279RecruitingPhase 3
Testing BCG treatment for bladder cancer after full tumor removal
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
Vancouver, British ColumbiaAges 18 years+ - NCT01050504Recruiting
Donate blood and tissue to study recurrent or metastatic cancers
This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.
Seattle, WashingtonAges 18 years+ - NCT06738251RecruitingPhase 3
Study of SHR-A2102 for advanced bladder cancer
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05595408Recruiting
Tracking tumor DNA to predict relapse after upper kidney cancer surgery
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07498907RecruitingPhase 3
Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
BeijingAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT06991868Recruiting
Urine test to monitor for urothelial cancer recurrence
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Beijing, Beijing MunicipalityAges 1.5 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Anchorage, AlaskaAges 18 years+ - NCT07321210Recruiting
Lymph node surgery for high-risk upper tract cancer
This trial compares removing the kidney and ureter alone versus also removing nearby lymph nodes for high-risk upper tract urothelial cancer. It aims to see if the extra step helps improve outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07029256Recruiting
Ultrasound-guided biopsy for bladder cancer staging
This trial uses an ultrasound-guided needle biopsy to check if bladder cancer has spread beyond the bladder. It may help doctors stage the cancer more accurately before surgery.
Rochester, MinnesotaAges 18 years+ - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT07532902RecruitingPhase 1
BMS-986504 with standard treatment for advanced solid tumors
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
Basking Ridge, New JerseyAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT03374267Recruiting
Urologic cancer registry study
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
Multiple LocationsAges 18 years+ - NCT07183319RecruitingPhase 2
ctDNA test in advanced bladder cancer
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Oklahoma City, OklahomaAges 18 years+ - NCT06822010RecruitingPhase 2
Gemcitabine and Mitomycin for High-Risk Upper Tract Cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
New Brunswick, New JerseyAges 18–99 - NCT07589413Recruiting
Blood markers and fluid absorption during bladder cancer surgery
This study looks at how fluid absorbed during bladder cancer removal surgery affects cell-free DNA (tiny pieces of cancer DNA) in your blood. Researchers want to understand if these blood markers can help predict surgery outcomes and guide treatment decisions.
Lanzhou, GansuAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Urothelial Carcinoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urothelial carcinoma recurrent?
- Yes. Clin2 currently lists 66 recruiting urothelial carcinoma recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urothelial carcinoma recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urothelial carcinoma recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.